Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders

Fingolimod (FTY720, Gilenya) was the first US Food and Drug Administration-approved oral therapy for relapsing forms of multiple sclerosis (MS). Research on modified fungal metabolites converged with basic science studies that had identified lysophospholipid (LP) sphingosine 1-phosphate (S1P) recept...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annual review of pharmacology and toxicology 2019-01, Vol.59 (1), p.149-170
Hauptverfasser:	Chun, Jerold, Kihara, Yasuyuki, Jonnalagadda, Deepa, Blaho, Victoria A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Central Nervous System - drug effects Central Nervous System - metabolism drugs Fingolimod Hydrochloride - pharmacology Fingolimod Hydrochloride - therapeutic use FTY720 Gilenya GPCRs Humans LPA lysophospholipids Lysophospholipids - metabolism medicines Multiple Sclerosis - drug therapy Multiple Sclerosis - metabolism neurodegeneration S1P Sphingosine-1-Phosphate Receptors - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!